Helping patients reclaim a life of possibility
On 15 October 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of talquetamab (Talvey®) to include combinations with daratumumab, either alone or together with pomalidomide, for myeloma patients who have received at least one previous line of treatment. The CHMP is the European Medicines Agency’s (EMA) committee responsible…
Chimeric antigen receptor (CAR) T-cell therapy is a treatment that uses genetically modified immune cells (T-cells) to treat myeloma. While clinical studies have demonstrated the strong efficacy of CAR T-cell therapies in this disease, many patients experience side effects that can persist for months or years after treatment. To inform myeloma patients and the myeloma…
On September 17, 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of melphalan flufenamide (melflufen, Pepaxti®) to third-line myeloma treatment. The CHMP is the European Medicines Agency’s (EMA) committee responsible for evaluating medicines and making recommendations on whether they should be approved for use…
As the International Myeloma Society (IMS) Annual Meeting is taking place this week, we caught up with myeloma expert Dr. Faith Davies, from NYU Langone, about her expectations for the meeting and why it is important for patient advocacy groups like MPE to attend. What are you looking forward to most about IMS 2026? I…
Myeloma Melodies, an awareness concert for myeloma, returns to Paris on 24 September for an evening of singing, music and fun. The concert is organised by Sarah Tullamore, a professional singer, vocal coach and voice-over artist based in Paris, who is using her voice for a cause close to her heart: raising awareness of myeloma.…
Myeloma Patients Europe (MPE) is attending and presenting at the International Myeloma Society (IMS) Annual Meeting taking place in Glasgow from 23–26 September 2026. The meeting, attended by over 3,000 delegates from around the world, features presentations on the most important data and topics in myeloma. MPE recently interviewed IMS President and member of the…
On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of teclistamab (Tecvayli®) to include its use in combination with daratumumab for adults with relapsed or refractory myeloma who have received at least one prior therapy. The CHMP is the European Medicines Agency’s (EMA) committee responsible for…
The European Hematology Association (EHA) 2026 Annual Congress, the largest haematology event in Europe, will take place from 11–14 June in Stockholm, Sweden. The congress will bring together experts from across the globe to present the latest advances in haematological diseases, including myeloma and AL amyloidosis. Myeloma Patients Europe (MPE) will be attending EHA to keep…